Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ironwood Pharmaceuticals (IRWD) EBITDA Margin (2016 - 2025)

Ironwood Pharmaceuticals' EBITDA Margin history spans 16 years, with the latest figure at 161.38% for Q4 2025.

  • For Q4 2025, EBITDA Margin fell 19616.0% year-over-year to 161.38%; the TTM value through Dec 2025 reached 4.97%, down 2153.0%, while the annual FY2025 figure was 4.97%, 2153.0% down from the prior year.
  • EBITDA Margin for Q4 2025 was 161.38% at Ironwood Pharmaceuticals, down from 61.84% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 666.87% in Q4 2023 and bottomed at 989.17% in Q2 2023.
  • The 5-year median for EBITDA Margin is 38.96% (2022), against an average of 21.19%.
  • The largest annual shift saw EBITDA Margin tumbled -102730bps in 2023 before it surged 101563bps in 2024.
  • A 5-year view of EBITDA Margin shows it stood at 35.32% in 2021, then increased by 29bps to 45.59% in 2022, then soared by 1363bps to 666.87% in 2023, then plummeted by -95bps to 34.78% in 2024, then tumbled by -564bps to 161.38% in 2025.
  • Per Business Quant, the three most recent readings for IRWD's EBITDA Margin are 161.38% (Q4 2025), 61.84% (Q3 2025), and 53.17% (Q2 2025).